File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer

TitleA multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer
Authors
Issue Date2003
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed
Citation
Respiratory Medicine, 2003, v. 97 n. 7, p. 796-803 How to Cite?
AbstractAims: To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naïve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) every 3 weeks for 6 cycles. Results: 130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% Cl: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis. Conclusion: Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC. © 2003 Elsevier Science Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/162700
ISSN
2015 Impact Factor: 3.036
2015 SCImago Journal Rankings: 1.396
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, JCMen_US
dc.contributor.authorTan, EHen_US
dc.contributor.authorLeong, SSen_US
dc.contributor.authorWang, CHen_US
dc.contributor.authorSun, Yen_US
dc.contributor.authorLi, Ren_US
dc.contributor.authorWahid, MIAen_US
dc.contributor.authorJusuf, Aen_US
dc.contributor.authorLiao, Men_US
dc.contributor.authorGuan, Zen_US
dc.contributor.authorHandoyo, Pen_US
dc.contributor.authorHuang, JSen_US
dc.contributor.authorChan, Ven_US
dc.contributor.authorLuna, Gen_US
dc.contributor.authorTsang, KWTen_US
dc.contributor.authorLam, WKen_US
dc.date.accessioned2012-09-05T05:22:29Z-
dc.date.available2012-09-05T05:22:29Z-
dc.date.issued2003en_US
dc.identifier.citationRespiratory Medicine, 2003, v. 97 n. 7, p. 796-803en_US
dc.identifier.issn0954-6111en_US
dc.identifier.urihttp://hdl.handle.net/10722/162700-
dc.description.abstractAims: To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naïve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) every 3 weeks for 6 cycles. Results: 130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% Cl: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis. Conclusion: Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC. © 2003 Elsevier Science Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmeden_US
dc.relation.ispartofRespiratory Medicineen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAsiaen_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung - Drug Therapy - Mortalityen_US
dc.subject.meshCisplatin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfusions, Intravenousen_US
dc.subject.meshLung Neoplasms - Drug Therapy - Mortalityen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPaclitaxel - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTaxoidsen_US
dc.titleA multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung canceren_US
dc.typeArticleen_US
dc.identifier.emailHo, JCM:jhocm@hku.hken_US
dc.identifier.authorityHo, JCM=rp00258en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0954-6111(03)00033-7en_US
dc.identifier.pmid12854629-
dc.identifier.scopuseid_2-s2.0-0038482181en_US
dc.identifier.hkuros82155-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038482181&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume97en_US
dc.identifier.issue7en_US
dc.identifier.spage796en_US
dc.identifier.epage803en_US
dc.identifier.isiWOS:000183882000006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHo, JCM=7402649981en_US
dc.identifier.scopusauthoridTan, EH=7402264078en_US
dc.identifier.scopusauthoridLeong, SS=7201555348en_US
dc.identifier.scopusauthoridWang, CH=7501645420en_US
dc.identifier.scopusauthoridSun, Y=8899511700en_US
dc.identifier.scopusauthoridLi, R=26642902100en_US
dc.identifier.scopusauthoridWahid, MIA=6603831703en_US
dc.identifier.scopusauthoridJusuf, A=6507230772en_US
dc.identifier.scopusauthoridLiao, M=7202371620en_US
dc.identifier.scopusauthoridGuan, Z=9744461700en_US
dc.identifier.scopusauthoridHandoyo, P=55292475100en_US
dc.identifier.scopusauthoridHuang, JS=10140800700en_US
dc.identifier.scopusauthoridChan, V=19834035000en_US
dc.identifier.scopusauthoridLuna, G=7006278378en_US
dc.identifier.scopusauthoridTsang, KWT=7201555024en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats